AstraZeneca PLC
AZN
$73.95
$0.861.18%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 27.14% | 33.82% | 56.25% | 4.00% | 6.00% |
| Total Depreciation and Amortization | 8.60% | 2.31% | -1.03% | 7.50% | 4.24% |
| Total Amortization of Deferred Charges | -- | -- | -28.57% | -- | -- |
| Total Other Non-Cash Items | -1,450.00% | 87.63% | 327.12% | 255.35% | 102.37% |
| Change in Net Operating Assets | -167.44% | 6.37% | -333.33% | -95.43% | 86.96% |
| Cash from Operations | 9.76% | 49.36% | 22.14% | 8.64% | 79.57% |
| Capital Expenditure | -72.51% | -2.88% | -34.86% | -30.72% | -41.48% |
| Sale of Property, Plant, and Equipment | -- | -98.11% | 100.00% | -100.00% | -100.00% |
| Cash Acquisitions | 88.38% | 61.81% | -26.85% | 3.66% | -1,148.37% |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -517.10% | 57.95% | 40.36% | -31.55% | -188.06% |
| Cash from Investing | 26.60% | 48.07% | -9.66% | -24.00% | -452.31% |
| Total Debt Issued | -57.12% | -81.61% | -1,221.57% | -1,192.11% | 4,391.43% |
| Total Debt Repaid | 95.76% | -4.94% | 67.04% | -59.07% | -84.99% |
| Issuance of Common Stock | -20.00% | 33.33% | 9.52% | 0.00% | 25.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 41.18% | -10.35% | -50.00% | -11.77% | 22.73% |
| Other Financing Activities | -- | 112.37% | -- | 152.17% | -- |
| Cash from Financing | 142.39% | -233.48% | -130.58% | -51.54% | 19.55% |
| Foreign Exchange rate Adjustments | 583.33% | 154.35% | -1,116.67% | 205.26% | 83.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 279.80% | -110.80% | -2.36% | -163.15% | -184.31% |